Traditional biomarkers in narcolepsy: experience of a Brazilian sleep centre

• Autor(a) principal: Coelho,Fernando Morgadinho Santos
• Data de Publicação: 2010
• Outros Autores: Pradella-Hallinan,Márcia, Pedrazzoli,Mario, Soares,Carlos Augusto Senne, Fernandes,Gustavo Bruniera Peres, Gonçalves,André Leite, Tufik,Sergio, Bittencourt,Lia Rita Azeredo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2010000500007
• topic: narcolepsy; cataplexy; cerebrospinal fluid; hypocretin-1; HLA-DQB1*0602; biomarkers

This study was thought to characterized clinical and laboratory findings of a narcoleptic patients in an out patients unit at São Paulo, Brazil. METHOD: 28 patients underwent polysomnographic recordings (PSG) and Multiple Sleep Latency Test (MSLT) were analyzed according to standard criteria. The analysis of HLADQB1*0602 allele was performed by PCR. The Hypocretin-1 in cerebral spinal fluid (CSF) was measured using radioimmunoassay. Patients were divided in two groups according Hypocretin-1 level: Normal (N) - Hypocretin-1 higher than 110pg/ml and Lower (L) Hypocretin-1 lower than 110 pg/ml. RESULTS: Only 4 patients of the N group had cataplexy when compared with 14 members of the L group (p=0.0002). DISCUSSION: This results were comparable with other authors, confirming the utility of using specific biomarkers (HLA-DQB1*0602 allele and Hypocretin-1 CSF level) in narcolepsy with cataplexy. However, the HLADQB1*0602 allele and Hypocretin-1 level are insufficient to diagnose of narcolepsy without cataplexy.